Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.32%, which has investors questioning if this is right time to buy.

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 12.39%, which has investors questioning if this is right time ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, ...

2025 I Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin ...

Charles Schwab Investment Management Inc. lowered its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 16.0% during the 4th quarter, Holdings Channel.com reports.

Lexicon Pharmaceuticals has been based in The Woodlands since its founding in 1995 under the name Lexicon Genetics, Inc. As of March 2025, the company employees about 103 people. Post-pandemic ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and ...